Venclexta (venetoclax tablets) — Cigna
Myelodysplastic Syndrome
Initial criteria
- Patient age ≥ 18 years
- Patient has chronic myelomonocytic leukemia-2 OR higher risk disease (IPSS-R intermediate-, high-, or very-high risk)
- Medication used in combination with azacitidine OR decitabine
Approval duration
1 year